MOTRIN CAPLET TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

IBUPROFEN

Предлага се от:

MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC

АТС код:

M01AE01

INN (Международно Name):

IBUPROFEN

дозиране:

200MG

Лекарствена форма:

TABLET

Композиция:

IBUPROFEN 200MG

Начин на приложение:

ORAL

Броя в опаковка:

24/50

Вид предписание :

OTC

Терапевтична област:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Каталог на резюме:

Active ingredient group (AIG) number: 0108883004; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2016-01-22

Данни за продукта

PRODUCT MONOGRAPH
MOTRIN
®
200 mg
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
Caplet
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
Gelcaps
Ibuprofen Tablets USP, 200 mg
MOTRIN
®
300 mg
Ibuprofen Tablets USP, 300 mg
MOTRIN
®
400 mg
Ibuprofen Tablets USP, 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
McNeil Consumer Healthcare
Division of Johnson & Johnson Inc.
88 McNabb Street
Markham, Canada
L3R 5L2
Date of Preparation:
May 10, 2002
Date of Revision:
February 26, 2015
Control # 181377
_ _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
.........................................................